Chronic Obstructive Pulmonary Disease
Inflammatory markers associated with COPD were linked to increased symptom burden, a greater number of exacerbations, and decreased 6-minute walk distance in smokers with preserved spirometry.
Wixela Inhub has been made available by Mylan for the treatment of asthma and COPD.
COPD is prone to false positive diagnoses.
A comprehensive research bronchoscopy procedure, including oral sampling, bronchoalveolar lavage, endobronchial biopsy, and brushing can be safely performed in COPD.
Compared with dual therapy, triple therapy was associated with reduced risk for severe exacerbation of COPD and better FEV1.
Mylan plans to make Wixela Inhub available in 3 strengths: 100mcg/50mcg, 250mcg/50mcg, and 500mcg/50mcg.
Nearly 6% of older adults account for more than 20% of emergency department visits.
In patients with moderate to severe COPD, indacaterol/glycopyrronium treatment is associated with improvements in regional ventilation and pulmonary microvascular blood flow.
The Depression, Anxiety, and Stress Scale (DASS-21) demonstrated validity in individuals with COPD underwent an 8-week pulmonary rehabilitation program.
The review showed supplementation was only effective for baseline vitamin D levels <25 nmol/L.
Hypertension and diabetes are especially prevalent comorbidities in obese patients with chronic obstructive pulmonary disease.
Influenza-positive patients have higher rates of crude mortality and critical illness vs influenza-negative patients.
Patients with comorbid stable COPD and chronic hypercapnic respiratory failure have improved symptoms and survival rates with high-intensity noninvasive ventilation.
The GOLD scientific committee published a report on current controversies in COPD, including the role of cigarette smoking vs biomass exposure, the role of thoracic imaging, and different treatment strategies.
The prevalence of overlap syndrome in obstructive sleep apnea and COPD in Medicare beneficiaries increased 4-fold from 2004 to 2013.
The COPD assessment test proved to be valid and reproducible in assessing the impact effect and severity of bronchiectasis symptoms in patients with COPD.
The odds of developing COPD were considerably higher in both men and women with class III obesity compared with normal weight individuals.
Cognitive behavioral therapy interventions were statistically and clinically superior to self-help leaflets in the treatment of anxiety in patients with COPD.
Patients with COPD who were considered frail were more likely to have lower quality of life, increased rate and length of hospitalization, and a higher rate of mortality.
Compared with usual care, a comprehensive 3-month program combining transition and long-term self-management support for patients with COPD led to significantly fewer COPD-related hospitalizations and greater quality of life.
A strong dose-response relationship was seen in never-smokers aged 50 and older.
Ottawa COPD Risk Scale is valid for predicting short-term serious outcomes for patients in the emergency department.
Blood eosinophil concentrations could be used to target patients with chronic obstructive pulmonary disease who are likely to respond to initial long-acting bronchodilator therapy.
Living in a rural community was a predictor for COPD prevalence, whether the individual had a history of smoking or was a current smoker.
The presence of COPD is linked to higher all-cause mortality and cardiac death at 24 hours in high-risk patients who present with ventricular tachyarrhythmias and sudden cardiac arrest.
Decreasing alpha diversity in the microbiome profile of sputum samples of patients hospitalized with COPD acute exacerbations was associated with increased 1-year mortality.
Nocturnal hypoxemia, along with COPD, increased the risk for cardiovascular events and mortality in female patients with suspected obstructive sleep apnea.
Healthcare providers should educate all patients with COPD about their flight-related risks and the need to seek medical advice before flying.
Bronchoscopic lung volume reduction with valve replacement shows the most promise for improving lung function, exercise tolerance, and quality of life in patients with advanced emphysema.
Compared with a combination treatment of LABA/LAMA, ICS/LABA/LAMA combination therapy was associated with a significantly greater pooled risk reduction in COPD exacerbation.